Trials / Conditions / AML (Acute Myelogenous Leukemia)

AML (Acute Myelogenous Leukemia)

20 registered clinical trials studyying AML (Acute Myelogenous Leukemia) — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	VEN+IDAC vs IDAC in AML NCT07537257	Guangdong Second Provincial General Hospital	Phase 2 / Phase 3
Enrolling By Invitation	Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials NCT07474051	AvenCell Therapeutics, Inc.	—
Recruiting	Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantati NCT07297576	Institute of Hematology & Blood Diseases Hospital, China	N/A
Recruiting	A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxi NCT06859424	Center for International Blood and Marrow Transplant Research	Phase 2
Recruiting	The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia NCT07232134	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 3
Recruiting	The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT NCT07126782	Institute of Hematology & Blood Diseases Hospital, China	EARLY_Phase 1
Recruiting	A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malign NCT07347171	Cullgen (Shanghai),Inc	Phase 1
Recruiting	CD123-CD16-NK Cells Immunotherapy for AML NCT06835140	Chunji Gao	Phase 1
Recruiting	Gut Health in Children With Cancer NCT06899581	Great Ormond Street Hospital for Children NHS Foundation Trust	—
Recruiting	Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT NCT06783790	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Recruiting	The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors NCT06911710	Tianjin Medical University General Hospital	Phase 1 / Phase 2
Recruiting	Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia NCT07014449	Hangzhou Weben Pharma Co., Ltd	Phase 1
Recruiting	Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combinat NCT07254312	Fondazione IRCCS Policlinico San Matteo di Pavia	—
Recruiting	Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML NCT06635681	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Recruiting	Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blocka NCT06874257	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Completed	Use of Venetoclax , AML , Sohag , Egypt NCT06993883	Sohag University	—
Completed	Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma NCT07254611	Fondazione IRCCS Policlinico San Matteo di Pavia	—
Terminated	Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Tra NCT02231853	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
Completed	Preventing Stem Cell Transplant Complications With a Blood Separator Machine NCT01866839	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 / Phase 2
Completed	Stem Cell Transplantation for Patients With Cancers of the Blood NCT00467961	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2